Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28348804 | 0.89 | PLK1 (0.53) | PLK1MTNR1AGFERDEGS1KDR | |
| SCHEMBL10274483 | 0.83 | PLK1 (0.67) | PLK1MTNR1AKDRAURKALCK | |
| SCHEMBL26885152 | 0.83 | AURKA (0.50) | PLK1GFERDEGS1KDRAURKA | |
| SCHEMBL1110584 | 0.82 | PLK1 (0.65) | PLK1MTNR1AKDRAURKALCK | |
| SCHEMBL8477167 | 0.81 | PLK1 (0.64) | PLK1MTNR1AGFERDEGS1GAA | |
| SCHEMBL23581544 | 0.81 | TLR8 (0.47) | GFERDEGS1GAATLR8PTPN1 | |
| SCHEMBL8191199 | 0.80 | PLK1 (1.00) | PLK1MTNR1ADEGS1GAAMMP3 | |
| SCHEMBL1150424 | 0.80 | PLK1 (1.00) | PLK1MTNR1ADEGS1GAAMMP3 | |
| SCHEMBL273978 | 0.80 | CA12 (0.54) | GFERGAATLR8PTPN1ALDH1A1 | |
| SCHEMBL30571222 | 0.80 | CA12 (0.54) | GFERGAATLR8PTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012645-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2015-04-21 | — | — | US | claimed |
| US-20140114075-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2014-04-24 | — | — | US | claimed |
| EP-2408739-B1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE SPA IN ABBREVIATED FORM EOS SPA (IT) | 2013-08-14 | — | — | EP | claimed |
| EP-2408739-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS Ethical Oncology Science S.p.A. In Abbreviated From EOS S.p.A. (IT) | 2012-01-25 | — | — | EP | claimed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | claimed |
| WO-2010105761-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2010-09-23 | — | — | WO | claimed |
| US-9783498-B2 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline | Advenchen Pharmaceuticals, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3103792-A1 | INTERMEDIATES FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE | Clovis Oncology Italy S.r.l. (IT) | 2016-12-14 | — | — | EP | disclosed |
| EP-3103792-A1 | INTERMEDIATES FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE | Clovis Oncology Italy S.r.l. (IT) | 2016-12-14 | — | — | EP | disclosed |
| CN-106187882-A | Prepare method and the synthetic intermediate thereof of compound | 克洛维斯肿瘤学意大利公司 | 2016-12-07 | — | — | CN | disclosed |
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| CN-104193676-B | Prepare method and the synthetic intermediate thereof of compound | 克洛维斯肿瘤学意大利公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-2641897-B1 | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S R L (IT) | 2016-07-13 | — | — | EP | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2005080313-A9 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2006-08-31 | — | — | WO | disclosed |
| EP-1660503-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140114075-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CYP2B6, CYP2A6, NAT1 | PLK1 2103/4885MTNR1A 630/4885GFER 1367/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | PLK1 3736/4885MTNR1A 166/4885GFER 2679/4885 |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | PLK1 4214/4885MTNR1A 526/4885GFER 3487/4885 |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CYP2B6, CYP2A6, NAT1 | PLK1 2104/4885MTNR1A 635/4885GFER 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.